ME00443B - Kristalni oblik tercijalne butilaminske soli perindoprila - Google Patents
Kristalni oblik tercijalne butilaminske soli perindoprilaInfo
- Publication number
- ME00443B ME00443B MEP-2008-673A MEP67308A ME00443B ME 00443 B ME00443 B ME 00443B ME P67308 A MEP67308 A ME P67308A ME 00443 B ME00443 B ME 00443B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- formula
- ethyl acetate
- crystalline form
- solution
- Prior art date
Links
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical class CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 238000010586 diagram Methods 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 19
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 13
- 229960002582 perindopril Drugs 0.000 claims description 13
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical class CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000001914 filtration Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000003940 butylamines Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
α kristalni oblik jedinjenja sa formulom (l) α kristalni oblik jedinjenja sa formulom (l) karakteriše se pomoću dijagrama praha. Lekovi. karakteriše se pomoću dijagrama prah a . L e kovi.
Description
Dati pronalazak odnosi se na novi a kristalni oblik tercijalne butilaminske soli perindoprila sa formulom (I):
na proces za njeno dobijanje i na farmaceutska jedinjenja koja je sadrže.
Perindopril i njegove farmaceutski prihvatljive soli, i još posebnije njegova butilaminska so, imaju značajna farmaceutska svojstva.
Njegovo najvažnije svojstvo je u tome da inhibira angiotenzin I koji prevodi enzim (ili kinazu II), koji sa jedne strane sprečava konverziju dekapeptida angiotenzina I u oktapeptidni angiotenzin II (vazokonstruktor) i sa druge strane degradaciju bradakina (vazodiletatora) do inaktivnog peptida.
Ova dve radnje odnose se na korisne efekte perindoprila kod kardiovaskularnih poremećaja, naročito arterijske hipertenzije i srčane slabosti.
Perindopril, njegovo dobijanje i njegova terapeutska upotreba opisani su u Evropskoj patentnoj prijavi EP 0 049 658.
U pogledu farmaceutske vrednosti ovog jedinjenja, od primarnog je značaja da se ono dobije u izvanredno čistom obliku. Takodje je značajno da je sposobno da se sintetizuje pomoću procesa koji se lako može konvertovati na skali industrijskih procesa, naročito u obliku koji dopušta ubrzano filtriranje i sušenje. Konačno, pomenuto jedinjenje mora biti potpuno spremno za ponovno dobijanje, lako formulisano i dovoljno stabilno da ostane postojano za duži vremenski period bez posebnih zahteva u pogledu temperature, svetlosti, vlažnosti ili nivoa kiseonika.
Patentna prijava EP 0 308 341 opisuje proces inustrijske sinteze za perindopril.
e jutim, ovaj dokument ne navodi uslove dobijanja perindoprila u obliku koji izražava ove karakteristike na način na koji se mogu ponoviti.
Prijavilac je pronašao da se posebna so perindoprila, terc-butilaminska so, može dobit, u dobro definisanom, lako primenljivom kristalnom obliku koji ima značajne karakteristike prilikom filtriranja, sušenja i održavanja formulacije.
Još specifičnije dati pronalazak se odnosi na kristalni oblik jedinjenja sa formulom (I) koji se karakteriše sledećim dijagramom praha, koji je meren korišćenjem Simensovog difraktometra D5005 (bakarna antikatoda) i koji je izražen u pogledu in er-p anarnog rastojanja d, Bragove ugla 2 teta, intenziteta i relativnog intenziteta (izraženog kao procenat od najintezivnijeg rendgentskog zraka).
Pronalazak se takodje odnosi na proces za dobijanje a kristalnog oblika jedinjenja sa formulom (I), gde se porces karakteriše time da se rastvor tercijalne butilaminske soli perindoprila u etil acetatu zagreva na refluksu i postepeno se hladi dok se proces kristalizacije ne završi
U procesu kristalizacije prema pronalasku moguće je koristiti jedinjenje sa formulom (I) koje se dobija u bilo kojem procesu. Koristi se jedinjenje sa formulom (I) dobijeno procesom opisanim u patentoj prijavi EP 0 308 341.
Koncentracija jedinjenja sa formulom (I) u etil acetatu je po mogućstvu od 70 do 90 g/litru.
Pogodno je da se rastvor jedinjenja sa formulom (I) u etil acetatu na refluksu prvo hladi do temperature od 55 do 65°C, brzinom od 5 do 10°C/sat, po mogućstvu od 6 do 8°C/sat, i onda do temperature okoline.
Rastvor kristalizuje tokom faze hladjenja na temperaturama izmedju 76 do 65°C.
Na taj način se tercijalna butilaminska so perindoprila dobija u obliku pojedinačnih iglica dužine oko 0. 2 mm. Ova homogena distribucija ima prednost zbog postizanja naročito brze i efikasne filtracije i sušenja, kao i dobijanja farmaceutskih formulacija koje imaju jednoobraznu kompoziciju koja se može lako dobiti, koja naročito ima prednost kada se ove formulacije koriste za oralnu primenu.
- procedura dovodjenja na nulu korišćenjem Simensovog razreza,
-eksperimentalni podaci dobijeni korišćenjem EVA softvera (verzija 5. 0).
PRIMER 1: α Kristalni oblik tercijalne butilaminske soli perindoprila
125 g tercijalne butilaminske soli perindoprila rastvoreno je u 1. 68 litara etil acetata zagrevanjem na refluksu, prema procesu opisanom u patentoj prijavi EP 0 308 341.
Temperatura rastvora se onda podešava do 60°C u vremenu od 2 sata i 30 minuta i onda se rastvor hladi do okolne temperature.
Čvrsti proizvod se dobija sakupljanjem procesom filtriranja.
Dijagram rendgentske difrakcije:
Profil rendgentske difrakcije (difrakcioni uglovi) za a oblik tercijalne butilaminske soli perindoprila dat je pomoću značajnih vrednosti rendgentskih zraka sakupljeni su u sledećoj tabeli zajedno sa intenzitetom i relativnim intenzitetom 9izraženim u procentima za najintezivniji rendgentski zrak).
PRIMER 2: Farmaceutska kompozicija
Preparativna formula za 100 tableta od kojih svaka sadrži 4 mg aktivnog sastojka:
Claims (7)
1. α kristalni oblik jedinjenja sa formulom (I): koji se karakteriše sledećim dijagramom praha, koji je meren korišćenjem difraktometra (bakarna antikatoda) i koji je izražen u pogledu inter-planarnog rastojanja d, Bragovog ugla 2 teta, intenziteta i relativnog intenziteta (izraženog kao procenat od najintezivnijeg rendgentskog zraka).
2. Proces za dobijanje a kristalnog oblika jedinjenja sa formulom (I) prema patentnom zahtevu 1, naznačen time, što se u tom rastvoru tercijalna butilaminska so perindoprila u etil acetatu zagreva na refluksu i nakon toga se postepeno hladi do završetka procesa kristalizacije.
3. Proces prema patentom zahtevu 2, naznačen time, što se koristi jedinjenje sa formulom (I) dobijeno procesom opisanim u patentoj prijavi EP 0 308 341.
4. Proces ili prema patentom zahtevu 2 ili prema patentnom zahtevu 3, naznačen time, što je koncentracija jedinjenja sa formulom (I) u etil acetatu od 70 do 90 g/litru.
5. Proces prema bilo kojem od patentnih zahteva od 2 do 4, naznačen time, što se rastvor jedinjenja sa formulom (I) u etil acetatu na refluksu prvo hladi do temperature od oko 55 do 65°C pri brzini zagrevanja od oko 5 do 10°C/na sat i nakon toga do okolne temperature.
6. Proces prema bilo kojem od patentih zahteva od 2 do 4, naznačen time, što rastvor jedinjenja sa formulom (I) u etil acetatu kristalizuje tokom faze hladjenja na temperaturama izmedju 76 do 65°C.
7. Proces prema patentnom zahtevu 5, naznačen time, što se rastvor jedinjenja sa formulom (I) u etil acetatu na refluksu prvo hladi do temperature od oko 55 do 65°C pri brzini zagrevanja od oko 5 do 10°C/na sat i nakon toga do okolne temperature.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0008793A FR2811320B1 (fr) | 2000-07-06 | 2000-07-06 | Nouvelle forme cristalline alpha du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| PCT/FR2001/002167 WO2001087835A1 (fr) | 2000-07-06 | 2001-07-06 | FORME CRISTALLINE α DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00443B true ME00443B (me) | 2011-10-10 |
Family
ID=8852172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-673A ME00443B (me) | 2000-07-06 | 2001-07-06 | Kristalni oblik tercijalne butilaminske soli perindoprila |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US20030186896A1 (me) |
| EP (1) | EP1296947B1 (me) |
| JP (2) | JP3602826B2 (me) |
| KR (1) | KR100513570B1 (me) |
| CN (1) | CN1328259C (me) |
| AP (1) | AP1537A (me) |
| AR (1) | AR034124A1 (me) |
| AT (1) | ATE258918T1 (me) |
| AU (2) | AU2001276418B2 (me) |
| BG (1) | BG64868B1 (me) |
| BR (1) | BR0112367A (me) |
| CA (1) | CA2415438C (me) |
| CZ (1) | CZ297672B6 (me) |
| DE (1) | DE60101968T2 (me) |
| DK (1) | DK1296947T3 (me) |
| EA (1) | EA005008B1 (me) |
| EE (1) | EE05268B1 (me) |
| ES (1) | ES2214434T3 (me) |
| FR (1) | FR2811320B1 (me) |
| GE (1) | GEP20043361B (me) |
| HR (1) | HRP20030077B1 (me) |
| ME (1) | ME00443B (me) |
| MX (1) | MXPA02012949A (me) |
| NO (1) | NO323447B1 (me) |
| NZ (1) | NZ523173A (me) |
| OA (1) | OA12304A (me) |
| PL (1) | PL206359B1 (me) |
| PT (1) | PT1296947E (me) |
| RS (1) | RS50915B (me) |
| SK (1) | SK285714B6 (me) |
| TR (1) | TR200400238T4 (me) |
| UA (1) | UA57188C2 (me) |
| WO (1) | WO2001087835A1 (me) |
| ZA (1) | ZA200210092B (me) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2811318B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2811319B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2838648B1 (fr) * | 2002-04-18 | 2004-05-21 | Servier Lab | Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent |
| GB2395195A (en) | 2002-11-18 | 2004-05-19 | Cipla Ltd | Preparation of perindopril from carboxy-protected precursor, & perindopril monohydrates for use as angiotensin converting enzyme (ACE) inhibitors |
| WO2004113293A1 (de) * | 2003-06-24 | 2004-12-29 | Les Laboratoires Servier | Neue kristalline formen von perindopril erbumine |
| BR0318561A (pt) * | 2003-10-21 | 2006-10-10 | Lupin Ltd | processo seletivo para a preparação de erbumino perindopril cristalino |
| SI21703A (en) | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia |
| LT1729739T (lt) * | 2004-03-29 | 2016-11-10 | Les Laboratoires Servier | Kietos farmacinės kompozicijos gamybos būdas |
| US20050250706A1 (en) * | 2004-05-07 | 2005-11-10 | Glenmark Pharmaceuticals Limited | Processes for the preparation of alpha polymorph of perindopril erbumine |
| WO2005108365A1 (en) * | 2004-05-07 | 2005-11-17 | Glenmark Pharmaceuticals Limited | Processes for the preparation of alpha polymorph of perindopril erbumine |
| SI21800A (sl) | 2004-05-14 | 2005-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nov postopek sinteze perindoprila |
| SI21881A (sl) | 2004-10-15 | 2006-04-30 | Diagen, Smartno Pri Ljubljani, D.O.O. | Nove kristalne oblike perindopril erbumin hidratov, postopek za njihovo pripravo in farmacevtske oblike, ki vsebujejo te spojine |
| SG125975A1 (en) * | 2005-03-11 | 2006-10-30 | Servier Lab | New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it |
| SG125976A1 (en) * | 2005-03-11 | 2006-10-30 | Servier Lab | New gama crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it |
| JP2006290825A (ja) * | 2005-04-13 | 2006-10-26 | Shiono Chemical Co Ltd | アルファ型ペリンドプリルエルブミンの製造法 |
| WO2007017894A2 (en) * | 2005-05-05 | 2007-02-15 | Arch Pharmalabs Limited | PREPARATION OF NOVEL CRYSTALLINE η(ETA) FORM OF PERINDOPRIL ERBUMINE |
| US20070032661A1 (en) * | 2005-08-03 | 2007-02-08 | Glenmark Pharmaceuticals Limited | Process for the preparation of intermediates of perindopril |
| MX2008002066A (es) * | 2005-08-12 | 2008-04-16 | Sandoz Ag | Neuva forma cristalina de perindopril-erbumina. |
| ATE502045T1 (de) * | 2005-08-12 | 2011-04-15 | Lek Pharmaceuticals | Verfahren zur herstellung von perindoprilerbumin |
| EP1815857A1 (en) | 2006-02-02 | 2007-08-08 | LEK Pharmaceuticals D.D. | A pharmaceutical composition comprising perindopril |
| WO2007092758A2 (en) * | 2006-02-03 | 2007-08-16 | Dr. Reddy's Laboratories Ltd. | Crystalline forms of perindopril erbumine |
| FR2897865B1 (fr) | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline beta du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| FR2897866B1 (fr) * | 2006-02-28 | 2008-04-18 | Servier Lab | Forme cristalline alpha du sel d'arginine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
| EA007988B1 (ru) * | 2006-04-20 | 2007-02-27 | ИСМАГИЛОВ, Искандар Халиуллович | ξ-ЗЕТА ФОРМА ПЕРИНДОПРИЛ ЭРБУМИНА |
| EP1964836A3 (en) * | 2006-11-06 | 2008-11-19 | IPCA Laboratories Limited | A process for the preparation of perindopril erbumine in alpha crystalline form |
| GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| WO2008114270A1 (en) * | 2007-03-22 | 2008-09-25 | Aarti Healthcare Limited | Process for the preparation of perindopril erbumine salt and novel polymorph (s) thereof |
| WO2008120241A2 (en) * | 2007-03-29 | 2008-10-09 | Ipca Laboratories Limited | Novel alcohol solvates of perindopril erbumine |
| AU2013201812B2 (en) * | 2007-06-27 | 2015-04-02 | Les Laboratoires Servier | Salts of perindopril |
| SI22543A (sl) * | 2007-06-27 | 2008-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Nove soli perindoprila |
| SI23149A (sl) * | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| PT105315B (pt) | 2010-09-29 | 2013-01-16 | Inst Superior Tecnico | Uma nova forma cristalina hidratada de erbumina de perindopril, métodos para a sua preparação e sua utilização em preparações farmacêuticas |
| CN103822996A (zh) * | 2014-03-20 | 2014-05-28 | 东英（江苏）药业有限公司 | 一种培哚普利叔丁胺盐含量的测定方法 |
| CN105395497B (zh) * | 2015-12-04 | 2019-06-18 | 杭州新诺华医药有限公司 | 一种稳定的α晶型培哚普利叔丁胺片及制备方法 |
| EP3842035A1 (en) | 2019-12-23 | 2021-06-30 | KRKA, d.d., Novo mesto | Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2503155A2 (fr) * | 1980-10-02 | 1982-10-08 | Science Union & Cie | Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme |
| FR2620744A1 (fr) * | 1987-09-17 | 1989-03-24 | Degremont | Procede de traitement par l'ozone de materiaux ligno-cellulosiques, notamment de pates a papier et reacteur pour la mise en oeuvre de ce procede |
| FR2620709B1 (fr) * | 1987-09-17 | 1990-09-07 | Adir | Procede de synthese industrielle du perindopril et de ses principaux intermediaires de synthese |
| FR2620703B1 (fr) * | 1987-09-17 | 1991-10-04 | Adir | Procede de synthese industrielle de l'acide perhydroindole carboxylique - 2(2s, 3as, 7as). application a la synthese de carboxyalkyl dipeptides |
| FR2771010B1 (fr) * | 1997-11-19 | 2003-08-15 | Adir | Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires |
| FR2811318B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline gamma du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
| FR2811319B1 (fr) * | 2000-07-06 | 2002-08-23 | Adir | Nouvelle forme cristalline beta du sel de tert-butylamine du perindopril, son procede de preparation et les compositions pharmaceutiques qui la contiennent |
-
2000
- 2000-07-06 FR FR0008793A patent/FR2811320B1/fr not_active Expired - Fee Related
-
2001
- 2001-06-07 UA UA2003021020A patent/UA57188C2/uk unknown
- 2001-07-06 WO PCT/FR2001/002167 patent/WO2001087835A1/fr not_active Ceased
- 2001-07-06 PL PL348492A patent/PL206359B1/pl unknown
- 2001-07-06 RS YUP-1004/02A patent/RS50915B/sr unknown
- 2001-07-06 JP JP2001584232A patent/JP3602826B2/ja not_active Expired - Fee Related
- 2001-07-06 AP APAP/P/2002/002691A patent/AP1537A/en active
- 2001-07-06 NZ NZ523173A patent/NZ523173A/en not_active IP Right Cessation
- 2001-07-06 MX MXPA02012949A patent/MXPA02012949A/es active IP Right Grant
- 2001-07-06 EE EEP200300001A patent/EE05268B1/xx not_active IP Right Cessation
- 2001-07-06 CA CA002415438A patent/CA2415438C/fr not_active Expired - Fee Related
- 2001-07-06 AR ARP010103226A patent/AR034124A1/es unknown
- 2001-07-06 BR BR0112367-0A patent/BR0112367A/pt not_active Application Discontinuation
- 2001-07-06 EA EA200300107A patent/EA005008B1/ru unknown
- 2001-07-06 PT PT01954058T patent/PT1296947E/pt unknown
- 2001-07-06 EP EP01954058A patent/EP1296947B1/fr not_active Revoked
- 2001-07-06 DE DE60101968T patent/DE60101968T2/de not_active Revoked
- 2001-07-06 DK DK01954058T patent/DK1296947T3/da active
- 2001-07-06 HR HR20030077A patent/HRP20030077B1/xx not_active IP Right Cessation
- 2001-07-06 US US10/312,961 patent/US20030186896A1/en not_active Abandoned
- 2001-07-06 GE GE5075A patent/GEP20043361B/en unknown
- 2001-07-06 AT AT01954058T patent/ATE258918T1/de active
- 2001-07-06 ME MEP-2008-673A patent/ME00443B/me unknown
- 2001-07-06 AU AU2001276418A patent/AU2001276418B2/en not_active Ceased
- 2001-07-06 SK SK149-2003A patent/SK285714B6/sk not_active IP Right Cessation
- 2001-07-06 AU AU7641801A patent/AU7641801A/xx active Pending
- 2001-07-06 KR KR10-2003-7000115A patent/KR100513570B1/ko not_active Expired - Fee Related
- 2001-07-06 CN CNB018123546A patent/CN1328259C/zh not_active Ceased
- 2001-07-06 ES ES01954058T patent/ES2214434T3/es not_active Expired - Lifetime
- 2001-07-06 OA OA1200200397A patent/OA12304A/en unknown
- 2001-07-06 TR TR2004/00238T patent/TR200400238T4/xx unknown
- 2001-07-06 CZ CZ20030357A patent/CZ297672B6/cs not_active IP Right Cessation
-
2002
- 2002-12-12 ZA ZA200210092A patent/ZA200210092B/xx unknown
-
2003
- 2003-01-03 NO NO20030024A patent/NO323447B1/no not_active IP Right Cessation
- 2003-02-05 BG BG107532A patent/BG64868B1/bg unknown
-
2004
- 2004-03-03 US US10/792,355 patent/US20050059609A1/en not_active Abandoned
- 2004-07-13 JP JP2004206158A patent/JP5016185B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00443B (me) | Kristalni oblik tercijalne butilaminske soli perindoprila | |
| JP3592296B2 (ja) | ペリンドプリルｔｅｒｔ−ブチルアミン塩の新しいγ結晶形、その製造方法及びこれを含む医薬組成物 | |
| ME00440B (me) | Novi $g(b kristalni oblik tercijalne butilaminske soli perindoprila, postupak dobijanja i farmaceutske kompozicije koje sadrže isto | |
| ME00353B (me) | 3-z-[1-(4-(n-((4-metil-piperazin-1-il)-metilkarbonil)-n-metil-amino)-anilino)-1-fenil-metilen]-6-metoksikarbonil-2-indolinon-monoetansulfonat i njegova primena u farmaceutskoj kompoziciji | |
| US5420155A (en) | Tetramic acid derivatives | |
| RS49708B (sr) | Oralne kompozicije levosimendana | |
| AU2007220434A1 (en) | Beta-crystalline form of perindopril arginine salt, method for making same, and pharmaceutical compositions containing same | |
| HU185324B (en) | Process for preparing 1-carboxy-azaalkanoyl-indoline-2-carboxylic acid derivatives | |
| JPS6253976A (ja) | 複素環式カルボン酸誘導体 | |
| EP1490333B1 (en) | New atorvastatin salts and pharmaceutical compositions containing them | |
| JP2007518668A (ja) | 結晶ペリンドプリルエルブミンの新規な調製方法 | |
| JPS59130255A (ja) | ベンゾイルチオ化合物、その製法及び医薬としての用途 | |
| Thornton et al. | Quinazoline antifolate thymidylate synthase inhibitors: difluoro-substituted benzene ring analogs | |
| Allen Jr et al. | 5-Substituted-1-indancarboxylic acids as potential antiinflammatory agents | |
| KR20180048939A (ko) | 안드로겐 수용체 억제제의 결정체 형태 및 그의 제조 방법 | |
| JPH04164071A (ja) | ヒダントイン誘導体およびその製造法 | |
| HK1095736B (en) | Use of r-(+)-2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxy-methyl-phenylisobutyric acid ester hydrogenfumarate for the treatment of urinary incontinence and other spasmogenic disorders | |
| HU225340B1 (en) | New alpha crystalline form of perindopril tert-butylamine salt, process for its preparation and pharmaceutical compositions containing it |